Thesis
MYQORZO launches across US, EU, and China; label expansion and commercial execution determine whether aficamten captures the full oHCM opportunity
MYQORZO (aficamten) is an approved cardiac myosin inhibitor for symptomatic obstructive HCM in adults, now commercializing across three major geographies with 680 U.S. patients prescribed in its first nine weeks. The thesis hinges on whether aficamten achieves durable commercial uptake against mavacamten (Bristol Myers Squibb's Camzyos) while securing the MAPLE-HCM sNDA approval to expand into the monotherapy-naive population. The primary risk is competitive displacement by Camzyos, which holds first-mover advantage and established payer relationships in the same oHCM patient population.
Focus
MAPLE-HCM sNDA FDA decision expected
2026-11-14
Bull
FDA approves the sNDA on the PDUFA date, incorporating the MAPLE-HCM data showing a +2.3 mL/kg/min superiority in peak VO2 versus metoprolol into the MYQORZO label; this comparative effectiveness claim becomes a powerful commercial tool that accelerates prescriber adoption beyond early enthusiasts, expands payer coverage, and positions MYQORZO as the preferred first-line myosin inhibitor — materially re-rating the revenue trajectory in the US.
Bear
FDA issues a complete response letter or requests additional data, leaving MYQORZO without a comparative effectiveness claim and forcing reliance on a symptomatic-improvement label shared with mavacamten; the most likely failure modes are a request for longer-term safety data on the head-to-head comparator design, labeling disputes around the exercise endpoint, or an advisory committee convened that raises questions about the clinical meaningfulness of the peak VO2 difference — all of which would delay differentiation and cede commercial ground to mavacamten.
Unlock the full thesis for CYTK.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.